Using Monoclonal Antibodies to Treat Mild to Moderate SARS-CoV-2 in Hemodialysis Patients
Recorded March 11, 2021
Monoclonal antibodies are one of the most recent treatments being considered for administration to dialysis patients in the early stages of COVID-19.
During this kidney community conversation, representatives from the CDC, HHS/ASPR, and outpatient dialysis care discussed options for administration to patients receiving hemodialysis.
Speakers for this 90-minute webinar include:
SARS-CoV-2 Variants
Pavithra Natarajan, BMBS
Centers for Disease Control and Prevention
Monoclonal Antibodies and the SPEED Program
LCDR David Foss, PharmD, MPH, BCPS, RAC
ASPR Allocation, Distribution and Administration Team
Clinical Trials in the General Population
Michael Anderson, MD
HHS/OS/ASPR
One Dialysis Organization’s Experience with Monoclonal Antibodies
Mary Dittrich, MD, FASN
US Renal Care
This conversation was moderated by Dr. Alan Kliger
This webinar, Use of Monoclonal Antibodies for the Treatment of Mild to Moderate SARS-CoV-2 in Patients Receiving Hemodialysis: A Kidney Community Conversation, is provided as information and education and should not be construed as medical advice or recommendations for patient care. The information expressed is that of the speaker(s) and contributor(s) only. Clinicians are to use their own training, clinical observations, and judgment to make all diagnostic and treatment decisions. The ASN Alliance (including ASN) does not offer medical advice.
